安進公司 AMGN 深 滬
已收盤 07-02 16:00:00 美东时间
374.15
+12.820
+3.55%
華盛通- 最 高375.15
- 今 開364.74
- 成交量 248.77万股
- 最 低 363.39
- 昨 收 361.33
- 總市值 2019.32亿
- 52周最高 388.77
- 市盈率 靜 26.30
- 換手率 0.46%
- 52周最低 262.35
- 委 比 4.37%
- 總股本 5.40亿
- 歷史最高 388.77
- 量 比 0.96
- 振 幅 3.25%
- 歷史最低 -30.959
- 每 手 1
- 風險率 31.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States
Sen. Elizabeth Warren (D-Mass) said a law signed by President Donald Trump a year earlier has already pushed large numbers of children off Medicaid and the Children’s Health Insurance Program across dozens of states. Her warning comes as she is also challenging Trump’s health-cost messaging, includi...
今天 02:08
Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line
Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen In...
07-03 00:30
Dogwood Therapeutics names OrbiMed’s Iain Dukes chair of new scientific advisory board
Dogwood Therapeutics names OrbiMed’s Iain Dukes chair of new scientific advisory board Dogwood Therapeutics named OrbiMed venture partner Iain Dukes chair of its newly formed Scientific Advisory Board. Dukes will advise leadership on scientific strategy for pain and neuropathy programs, including Ha
06-30 20:45
补税4.46亿，10年耗资700亿亏损超80亿，百济神州“微妙平衡术”还能继续吗？
日前，百济神州（688235.SH）发布公告称，一家境内全资子公司于近日收到当地主管税务部门通知，被要求及时补缴税款及滞纳金共计约人民币4.46亿元。 这笔税款...
06-30 17:56
Biovitrum痛风疗法未获FDA批准 公司股价下跌3%
瑞典孤儿生物制药公司（Sobi，斯德哥尔摩交易所代码:SOBIV）用于难治性痛风的在研疗法NASP的生物制品许可申请，收到美国食品药品监督管理局的完整回应函，被...
06-29 16:07
安进15分钟走势图显示RSI超卖且KDJ金叉
安进公司15分钟股价走势相关技术指标出现关键信号：其相对强弱指数（RSI）已进入超卖区间，随机指标（KDJ）于2026年6月26日15时15分形成金叉。 当前安...
06-27 03:23
Lilly, Incyte, CSL among winners of EU drug recommendations this week
An expert panel of the EU drug regulator, the European Medicines Agency, endorsed six new medicines and 11 label expansions for approval this week, benefiting drugmakers including Eli Lilly (LLY), Inc...
06-26 22:29
Amgen faces EU withdrawal of rare-disorder therapy Tavneos
Amgen (AMGN) is facing a possible EU withdrawal of its rare-disorder therapy, Tavneos, after an expert panel of the European Medicines Agency recommended its marketing authorization be revoked due to ...
06-26 19:36
EMA recommends revoking marketing authorisation for Amgen's rare disease drug
EMA recommends revoking marketing authorisation for Amgen's rare disease drug June 26 (Reuters) - The European Medicines Agency on Friday recommended revoking the marketing authorisation for Amgen's AMGN.O rare disease drug Tavneos. (Reporting by Christy Santhosh in Bengaluru; Editing by Shreya Bisw
06-26 18:53
